$871 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 113 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 60.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $19,698,000 | -1.2% | 141,700 | -11.7% | 2.26% | -17.7% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $12,293,000 | -35.9% | 76,116 | -47.5% | 1.41% | -46.6% |
| RTRX | Sell | RETROPHIN INC | $9,357,000 | -2.8% | 325,678 | -7.8% | 1.07% | -19.1% |
| MSFT | Sell | MICROSOFT CORP | $7,967,000 | +8.5% | 69,656 | -6.4% | 0.92% | -9.6% |
| PRQR | Sell | PROQR THRAPEUTICS N V | $7,716,000 | +114.1% | 398,749 | -19.2% | 0.89% | +78.3% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $7,581,000 | +59.4% | 92,719 | -31.8% | 0.87% | +32.6% |
| ZFGN | Sell | ZAFGEN INC | $5,027,000 | +2.4% | 430,000 | -10.4% | 0.58% | -14.8% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $5,009,000 | +24.0% | 379,484 | -13.6% | 0.58% | +3.2% |
| KDMN | Sell | KADMON HLDGS INC | $4,977,000 | -19.7% | 1,490,000 | -4.0% | 0.57% | -33.1% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $4,539,000 | +15.1% | 212,000 | -7.0% | 0.52% | -4.2% |
| MLNX | Sell | MELLANOX TECHNOLOGIES LTD | $3,679,000 | -49.2% | 50,093 | -41.7% | 0.42% | -57.8% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $3,501,000 | -81.8% | 40,000 | -79.5% | 0.40% | -84.8% |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $2,758,000 | -25.2% | 321,430 | -4.3% | 0.32% | -37.7% |
| LPTX | Sell | LEAP THERAPEUTICS INC | $2,590,000 | -42.3% | 332,525 | -33.4% | 0.30% | -52.0% |
| FLEX | Sell | FLEX LTDord | $2,093,000 | -42.9% | 159,549 | -38.6% | 0.24% | -52.5% |
| VRCA | Sell | VERRICA PHARMACEUTICALS INC | $1,901,000 | -23.4% | 117,000 | -7.0% | 0.22% | -36.3% |
| SRRA | Sell | SIERRA ONCOLOGY INC | $1,739,000 | -45.4% | 1,022,759 | -4.9% | 0.20% | -54.4% |
| SESN | Sell | SESEN BIO INC | $1,355,000 | -70.8% | 630,000 | -73.5% | 0.16% | -75.6% |
| KMPH | Exit | KEMPHARM INC | $0 | – | -22,622 | -100.0% | -0.02% | – |
| MHK | Exit | MOHAWK INDS INC | $0 | – | -1,100 | -100.0% | -0.03% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -20,410 | -100.0% | -0.08% | – |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -34,475 | -100.0% | -0.09% | – |
| AQXP | Exit | AQUINOX PHARMACEUTICALS INC | $0 | – | -257,613 | -100.0% | -0.09% | – |
| RDCM | Exit | RADCOM LTD | $0 | – | -52,760 | -100.0% | -0.14% | – |
| DK | Exit | DELEK US HLDGS INC NEW | $0 | – | -24,533 | -100.0% | -0.17% | – |
| KRNT | Exit | KORNIT DIGITAL LTD | $0 | – | -130,831 | -100.0% | -0.32% | – |
| MRVL | Exit | MARVELL TECHNOLOGY GROUP LTDord | $0 | – | -109,842 | -100.0% | -0.32% | – |
| APTX | Exit | APTINYX INC | $0 | – | -102,474 | -100.0% | -0.34% | – |
| LRCX | Exit | LAM RESEARCH CORP | $0 | – | -14,597 | -100.0% | -0.35% | – |
| ELOX | Exit | ELOXX PHARMACEUTICALS INC | $0 | – | -167,474 | -100.0% | -0.39% | – |
| WIX | Exit | WIX COM LTD | $0 | – | -29,542 | -100.0% | -0.41% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -20,000 | -100.0% | -0.47% | – |
| FB | Exit | FACEBOOK INCcl a | $0 | – | -19,100 | -100.0% | -0.51% | – |
| CTIC | Exit | CTI BIOPHARMA CORP | $0 | – | -874,407 | -100.0% | -0.60% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -213,625 | -100.0% | -0.76% | – |
| NICE | Exit | NICE LTDsponsored adr | $0 | – | -60,043 | -100.0% | -0.86% | – |
| SODA | Exit | SODASTREAM INTERNATIONAL LTD | $0 | – | -73,762 | -100.0% | -0.87% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -351,953 | -100.0% | -0.88% | – |
| INNT | Exit | INNOVATE BIOPHARMACEUTICLS I | $0 | – | -980,502 | -100.0% | -1.08% | – |
| AGN | Exit | ALLERGAN PLC | $0 | – | -60,000 | -100.0% | -1.38% | – |
| PFE | Exit | PFIZER INC | $0 | – | -390,000 | -100.0% | -1.95% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -50,000 | -100.0% | -2.00% | – |
| AMGN | Exit | AMGEN INC | $0 | – | -100,000 | -100.0% | -2.54% | – |
| SHPG | Exit | SHIRE PLCsponsored adr | $0 | – | -126,500 | -100.0% | -2.94% | – |
| Exit | ISHARES TRput | $0 | – | -150,000 | -100.0% | -3.39% | – | |
| Exit | SPDR SERIES TRUSTput | $0 | – | -750,000 | -100.0% | -9.84% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.